PetMed Express, Inc. filings document the regulatory record for a Florida public company operating the PetMeds and PetCareRx pet pharmacy businesses. Annual and current reports disclose operating results, non-GAAP reconciliations, intangible-asset impairment matters involving the PCRX trade name, and the financial reporting issues reflected in Forms 12b-25 and Nasdaq continued-listing notices.
Other filings cover governance and capital-structure matters, including annual meeting voting results, director elections, executive compensation advisory votes, audit committee composition, amendments to the shareholder rights agreement, and modifications to security holder rights. The record also includes Form 8-K disclosures for material agreements, board appointments, results releases, and listing compliance communications.
PetMed Express reported first quarter results for the period ended June 30, 2026. Net sales were $41.0 million, down 19.9% from $51.2 million a year earlier as lower consumer promotional usage was more than offset by weaker prescription medication sales. Net loss was $6.1 million, or $(0.28) per diluted share, a substantial improvement from a $34.2 million loss, or $(1.65) per share, primarily due to the absence of prior-year goodwill and trade name impairment charges and lower general and administrative and advertising expenses, partially offset by lower gross profit.
Adjusted EBITDA was $(3.4) million, compared with $(2.7) million in the prior-year quarter, reflecting a $0.8 million decline. Operating cash use improved but remained negative, with net cash used in operating activities of $7.7 million versus $12.3 million a year earlier. Cash and cash equivalents were $13.1 million at June 30, 2026, down from $21.4 million at March 31, 2026. Management highlighted more efficient marketing with 70,000 new customers and a 15% lower acquisition cost, nearly 14% lower general and administrative expenses, completion of an SAP ERP rollout, and a recently announced sale-leaseback intended to strengthen the balance sheet.
PetMed Express, Inc. reported results of its 2026 Annual Meeting of Shareholders and an amendment to its equity compensation plan. Shareholders approved a 2026 Plan Amendment to the PetMed Express, Inc. 2024 Omnibus Incentive Plan, increasing the shares of common stock reserved for issuance under the plan by 1,800,000 shares.
As of the June 15, 2026 record date, 21,371,880 voting shares were outstanding, and 14,291,482 shares were represented in person or by proxy, constituting a quorum. Four director nominees were elected, shareholders approved on an advisory basis the compensation of named executive officers, ratified Baker Tilly US, LLP as independent registered public accounting firm for fiscal year 2026, and approved the amendment to the 2024 Omnibus Incentive Plan.
LaCamp James reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express IncJames LaCamp55,555 sharesAugust 11, 202790,421 shares
Batushansky Peter reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express Inc. director Peter Batushansky reported a grant of 55,555 shares of common stock as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan. The award vests in full on August 11, 2027, subject to his continued service on the Board of Directors, bringing his direct holdings to 91,928 shares.
Mennen Justin L. reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express Inc. director Justin L. Mennen received a grant of 55,555 shares of Common Stock as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan. These shares vest in full on August 11, 2027, subject to his continued service on the Board of Directors.
After this award, Mennen directly holds 98,274 shares of PetMed Express common stock.
KRULIK DOUGLAS reported acquisition or exercise transactions in this Form 4 filing.
PETMED EXPRESS INC reported equity awards to CAO and Interim CFO Douglas Krulik effective June 26, 2026. He received 32,500 restricted common shares that vest 50% on June 26, 2027 and 50% on June 26, 2028, plus 32,500 performance share units tied to total shareholder return from April 1, 2026 to March 31, 2028.
The amended insider report corrects the PSUs’ performance period description and aligns their March 31, 2028 expiration date; it states no other changes. Following the restricted stock grant, Krulik directly holds 102,500 common shares.
PetMed Express, through its wholly owned subsidiary 420 South Congress Avenue, LLC, has agreed to a sale-leaseback of its Delray Beach, Florida headquarters and related property with Redfearn Capital Acquisitions, LLC for an aggregate purchase price of $37.0 million. The buyer will place a $0.5 million initial deposit and an additional $1.7 million deposit after a Due Diligence Period of up to 30 days, which may be extended by up to 45 days, with closing 30 days after that period, subject to customary conditions and completion of lease negotiations.
At closing, PetMed Express is expected to enter into a 120‑month, triple‑net lease for 100,519 square feet at 420 South Congress Avenue, with first‑year base rent of $15.25 per square foot and 3.5% annual increases. The lease will include three consecutive five‑year extension options at fair‑market‑value starting rents, a cap on property management fees at 4% of gross rent, and requirements to prepay the third year of base rent and provide a security deposit equal to one year’s rent. The company anticipates completing the transaction within 120 days and describes monetizing its real estate as part of its efforts to strengthen its balance sheet, focus on its core pharmacy business, and retain long‑term use of its current headquarters.
SilverCape Investments Limited, a Cayman Islands investor, has filed an amended Schedule 13D stating it holds 2,579,696 shares of PetMed Express common stock, or about 12.07% of the company based on 21,365,782 shares outstanding as of May 22, 2026.
On June 29, 2026, SilverCape sent a revised non-binding proposal to PetMed Express’ CEO and board to take the company private by acquiring 100% of the outstanding common stock for $3.00 per share in cash. The proposal is subject to further due diligence and negotiation and would require a mutually acceptable definitive agreement, including board actions to neutralize the company’s shareholder rights plan or other antitakeover protections. The filing emphasizes there is no assurance a definitive agreement will be signed or that any transaction will be completed, and that SilverCape may change, withdraw, or further pursue its proposal at any time.
PetMed Express, Inc. reported a pending change in its board of directors. On June 23, 2026, director Leah A. Solivan notified the company that she will not stand for reelection at the 2026 annual meeting of stockholders, scheduled for August 11, 2026.
She will continue to serve as a director until that meeting. The company states that her decision is not due to any disagreement with PetMed Express or its board regarding operations, policies, or practices, indicating a routine board transition rather than a conflict-driven departure.
KRULIK DOUGLAS reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express granted CAO and interim CFO Douglas Krulik 32,500 shares of restricted common stock and 32,500 performance share units as equity compensation. The restricted shares vest 50% on June 26, 2027 and 50% on June 26, 2028, while the performance units payout depends on three-year relative total shareholder return through December 31, 2028.